Causal inference methods for small non-randomized studies: Methods and an application in COVID-19
The usual development cycles are too slow for the development of vaccines, diagnostics and treatments in pandemics such as the ongoing SARS-CoV-2 pandemic. Given the pressure in such a situation, there is a risk that findings of early clinical trials are overinterpreted despite their limitations in terms of size and design. Motivated by a non-randomized open-label study investigating the efficacy of hydroxychloroquine in patients with COVID-19, we describe in a unified fashion various alternative approaches to the analysis of non-randomized studies.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Sarah Friedrich, Tim Friede Source Type: research
More News: Clinical Trials | COVID-19 | Hydroxychloroquine | Pandemics | Radiology | SARS | Study | Vaccines